ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Expected to Announce Earnings of $0.08 Per Share

Analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating) to announce $0.08 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for ANI Pharmaceuticals’ earnings. ANI Pharmaceuticals posted earnings per share of $1.04 during the same quarter last year, which indicates a negative year over year growth rate of 92.3%. The company is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that ANI Pharmaceuticals will report full year earnings of $1.12 per share for the current financial year, with EPS estimates ranging from $1.11 to $1.12. For the next fiscal year, analysts anticipate that the firm will report earnings of $2.70 per share, with EPS estimates ranging from $2.62 to $2.78. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last announced its quarterly earnings data on Tuesday, March 15th. The specialty pharmaceutical company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.31). The business had revenue of $60.93 million for the quarter, compared to the consensus estimate of $58.25 million. ANI Pharmaceuticals had a positive return on equity of 14.10% and a negative net margin of 19.71%. During the same quarter in the prior year, the company earned $0.65 earnings per share.

Several research firms recently commented on ANIP. StockNews.com started coverage on ANI Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating for the company. Raymond James dropped their target price on ANI Pharmaceuticals from $65.00 to $47.00 and set an “outperform” rating on the stock in a report on Wednesday, March 16th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ANI Pharmaceuticals in a report on Wednesday, March 16th. TheStreet lowered ANI Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Wednesday, March 30th. Finally, Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, March 14th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $56.67.

In related news, CEO Nikhil Lalwani acquired 7,224 shares of ANI Pharmaceuticals stock in a transaction on Monday, March 21st. The shares were bought at an average cost of $27.69 per share, with a total value of $200,032.56. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick D. Walsh bought 5,000 shares of the business’s stock in a transaction dated Monday, March 21st. The shares were acquired at an average cost of $27.76 per share, for a total transaction of $138,800.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 17,224 shares of company stock valued at $477,083. 27.20% of the stock is owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue increased its position in shares of ANI Pharmaceuticals by 15.4% in the 1st quarter. State of Alaska Department of Revenue now owns 8,846 shares of the specialty pharmaceutical company’s stock valued at $248,000 after acquiring an additional 1,180 shares during the period. Barclays PLC lifted its stake in ANI Pharmaceuticals by 105.3% in the 4th quarter. Barclays PLC now owns 15,966 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 8,190 shares in the last quarter. BlackRock Inc. lifted its stake in ANI Pharmaceuticals by 11.6% in the 4th quarter. BlackRock Inc. now owns 1,686,613 shares of the specialty pharmaceutical company’s stock worth $77,721,000 after purchasing an additional 174,984 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of ANI Pharmaceuticals by 13.0% during the 4th quarter. Wells Fargo & Company MN now owns 19,668 shares of the specialty pharmaceutical company’s stock worth $907,000 after buying an additional 2,264 shares during the last quarter. Finally, William Blair Investment Management LLC increased its holdings in shares of ANI Pharmaceuticals by 20.7% during the 4th quarter. William Blair Investment Management LLC now owns 451,444 shares of the specialty pharmaceutical company’s stock worth $20,803,000 after buying an additional 77,338 shares during the last quarter. 53.51% of the stock is currently owned by institutional investors and hedge funds.

Shares of ANIP stock opened at $32.16 on Monday. The stock has a market cap of $555.47 million, a price-to-earnings ratio of -9.90 and a beta of 1.18. The stock has a 50-day moving average of $33.22 and a 200-day moving average of $39.35. The company has a current ratio of 3.68, a quick ratio of 2.74 and a debt-to-equity ratio of 0.86. ANI Pharmaceuticals has a 1-year low of $24.41 and a 1-year high of $60.23.

ANI Pharmaceuticals Company Profile (Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

See Also

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.